Cathie Wood’s ARK Invest Boosts Biotech Holdings, Trims Roku Stake
Cathie Wood's ARK Invest ETFs made significant moves on September 3, 2025, doubling down on gene-editing biotech plays while reducing exposure to streaming giant Roku. The ARK Innovation ETF (ARKK) acquired $2.1 million worth of CRISPR Therapeutics (CRSP) shares, following a $2.9 million purchase the previous day.
Intellia Therapeutics (NTLA) saw $607,000 in fresh investments from ARKK, building on a $1.9 million position established just 24 hours earlier. These consecutive buys signal Wood's conviction in the gene-editing sector's long-term potential, even as she rebalances the portfolio by cutting Roku holdings.